Cardiomyopathy Trial, Recruiting NCT06814587 Sponsor: University of Texas Southwestern Medical Center Condition: Cardiomyopathy
Back to Cardiomyopathy

Cardiomyopathy Trial, Recruiting

NCT06814587
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

For people with ischemic heart disease (heart disease caused by blocked arteries):

  • Adults between 18 and 80 years old (male or female)
  • People who have been scheduled for coronary artery bypass graft (CABG) heart surgery as part of their regular medical care
  • People who have one or more narrowed or blocked coronary arteries (the blood vessels that supply the heart)
  • People whose heart pumping strength is 40% or less, or who have been referred for a heart viability assessment
  • People who are able to follow the preparation steps for the imaging scans, such as fasting and managing blood sugar levels before the scan
  • Current medications taken within 24 hours of the scan are permitted and will be recorded
  • Females of childbearing age who have a negative pregnancy test on the day of scanning
  • People with no known reasons they cannot safely have a 3T MRI, a SPECT scan, or an FDG PET scan

For healthy volunteers:

  • Adults between 18 and 80 years old (male or female)
  • People with no history of coronary artery disease or diabetes
  • People who are medically suitable for a 3T MRI, SPECT scan, and FDG PET scan
  • Females of childbearing age who have a negative pregnancy test on the day of scanning

Who may not be able to join:

For people with ischemic heart disease:

  • People younger than 18 or older than 80 years of age
  • People who are not scheduled for CABG surgery, or who do not have a confirmed diagnosis of coronary artery disease
  • People with a history of a heart attack that left more than 50% of the heart wall permanently scarred (based on prior imaging or medical history)
  • People who cannot safely undergo a 3T MRI (for example, due to a pacemaker, defibrillator, or metal implants), a SPECT scan (for example, due to significant irregular heartbeat or unstable blood pressure), or an FDG PET scan (for example, due to severely impaired blood sugar processing)
  • Females who have a positive pregnancy test or who are currently breastfeeding on the day of scanning
  • People with severely reduced kidney function (confirm with trial site)
  • People with poorly controlled diabetes, specifically a long-term blood sugar level (HbA1c) above 9%, or those who are unable to reach stable blood sugar levels before the scan

For healthy volunteers:

  • People with a history of coronary artery disease, diabetes, or other medical conditions that the study team determines would make participation unsuitable
  • Females who have a positive pregnancy test or who are currently breastfeeding on the day of scanning
  • People with reasons they cannot safely have an MRI (such as metal implants or claustrophobia), a SPECT scan, or an FDG PET scan

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Gaurav Sharma, PhD, MBA, University of Texas Southwestern Medical Center

Phone: 214-645-7700

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 July 2024
Est. completion
30 June 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Assessment of Myocardial Metabolism and Viability via HP-13C MRI, FDG-PET, and SPECT MPI

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov